NASDAQ:CDXS - Codexis Stock Price, Forecast & News

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported $0.01 EPS for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.10. The biotechnology company earned $21.91 million during the quarter, compared to analysts' expectations of $16.56 million. Codexis had a negative return on equity of 15.24% and a negative net margin of 17.85%. View Codexis' Earnings History.

Codexis is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Codexis.

2 brokerages have issued twelve-month price objectives for Codexis' shares. Their forecasts range from $22.50 to $25.00. On average, they expect Codexis' share price to reach $23.75 in the next twelve months. This suggests a possible upside of 69.9% from the stock's current price. View Analyst Price Targets for Codexis.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.

News stories about CDXS stock have trended neutral recently, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Codexis earned a daily sentiment score of 0.1 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Codexis.

Codexis saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,410,000 shares, an increase of 8.4% from the January 15th total of 4,990,000 shares. Based on an average daily trading volume, of 335,000 shares, the short-interest ratio is presently 16.1 days. Approximately 10.1% of the company's shares are sold short. View Codexis' Current Options Chain.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Canopy Growth (CGC), AbbVie (ABBV), Antares Pharma (ATRS), Alibaba Group (BABA), Corbus Pharmaceuticals (CRBP), Cisco Systems (CSCO), Xilinx (XLNX) and AT&T (T).

Codexis' stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (6.47%), William Blair Investment Management LLC (2.96%), Janus Henderson Group PLC (2.57%), Nikko Asset Management Americas Inc. (2.35%), Sumitomo Mitsui Trust Holdings Inc. (2.35%) and FMR LLC (2.33%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Institutional Ownership Trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prescott Group Capital Management L.L.C., FMR LLC, Oak Ridge Investments LLC, Stifel Financial Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Bank of America Corp DE. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols and Thomas R Baruch. View Insider Buying and Selling for Codexis.

CDXS stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Baillie Gifford & Co., Janus Henderson Group PLC, Aviva PLC, Essex Investment Management Co. LLC, Goldman Sachs Group Inc., Barclays PLC and Marshall Wace LLP. Company insiders that have bought Codexis stock in the last two years include John J Nicols and Patrick Y Yang. View Insider Buying and Selling for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $13.98.

Codexis has a market capitalization of $817.82 million and generates $60.59 million in revenue each year. The biotechnology company earns $-10,880,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.View Additional Information About Codexis.

The official website for Codexis is http://www.codexis.com/.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]